Ola A. Harb
Zagazig University, Zagazig, Egypt
Title: Beclin-1 Expression is a Predictor of Clinical Outcome in Patients with Serous Ovarian Carcinoma and Correlated to Hypoxia-Inducible Factor (HIF)-1α Expression
Biography
Biography: Ola A. Harb
Abstract
In the present study, we examined the relationship between Beclin-1 expression and HIF-1α expression in 60 cases of serous ovarian carcinoma (SOC) using immunohistochemistry.
We followed our patients for 3 years, analyzed the relationship between markers expression, clinic-pathological criteria and the prognosis of patients.
Results: the expression of Beclin-1 in SOC was significantly negatively correlated with advanced age of the patients (p=0.003), higher grade (p=0.002)& advanced stage of the tumor, presence of distant metastases (p<0.001), peritoneal implants (p=0.006), L.N metastases (p=0.004), bilaterality (p=0.03) and ascites (p=.005), the expression of HIF-1α in SOC was significantly positively correlated with advanced age of the patients (p=0.002), higher grade of the tumor, presence of peritoneal implants (p=0.006), advanced stage of the tumor (p=0.007), presence of distant metastases (p=0.012), peritoneal implants (p=0.044), L.N metastases (p<0.001), and presence of ascites (p=.036).
High Beclin-1 and Low HIF-1α expression were strongly correlated with better response to therapy (p=0.047& 0.022 respectively), increased Chemosensitivity of the tumor (p=0.043& 0.036 respectively), low incidence of recurrence after therapy (p=0.006 & <0.001 respectively), increased the liability of optimal surgical eradication of the tumor, increased 3-year recurrence free overall survival rates (P <0.001). Beclin-1 expression was negatively correlated with HIF-1α expression r correlation coefficient= -0.762 (p<0.001).
Conclusion: Beclin-1 is a marker of good prognosis, while HIF-1α is a marker of poor prognosis in SOC.
Keywords: Beclin-1; HIF-1α; serous ovarian carcinoma; immunohistochemistry; prognosis